melanoma Archives

Luke and Susan Simons recently made a gift to establish the Susan and Luke Simons Directorship at Vanderbilt-Ingram Cancer Center.

Couple’s gift helps support immunotherapy research

Aug. 11, 2022—Luke and Susan Simons have endowed a new directorship that will support research so that more people can benefit from immunotherapies.

Melanoma treatment response

Feb. 24, 2022—Targeting the interaction between melanoma and immune cells could improve responses to targeted cancer therapies, Vanderbilt researchers found.

Preclinical study supports rigosertib as booster to immunotherapy treatment for melanoma

Jul. 1, 2021—A team of Vanderbilt researchers have shown in a preclinical study that the investigational drug rigosertib could be a potential booster treatment to elicit response to immunotherapies among melanoma patients.

Forty-three percent of melanoma patients have chronic complications from immunotherapies

Mar. 25, 2021—Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.

Ann Richmond, MD, Chi Yan, PhD, Jinming Yang, PhD, and colleagues are studying ways to boost antitumor immunity and reduce tumor growth in breast cancer and melanoma.

Study reveals new strategy for reducing tumor growth, metastasis

Dec. 17, 2020—A team of Vanderbilt investigators has discovered that blocking a certain signaling pathway boosts antitumor immunity and reduces tumor growth and metastasis in models of breast cancer and melanoma.

Study explores melanoma drug’s effectiveness

Apr. 23, 2020—A study by Vanderbilt research-ers supports the clinical development of a new second-line treatment for metastatic melanoma.

Potential second-line melanoma treatment identified

Aug. 15, 2019—A study led by Anna Vilgelm, MD, PhD, and Ann Richmond, PhD, has identified a possible second-line treatment for melanoma patients.

Hot chemotherapy surgery helps save patient’s leg

Mar. 28, 2019—Tom Deweese can keep up with his grandchildren because of a highly specialized surgery using hot chemotherapy that saved his leg.

Entertainers’ support strengthens VICC melanoma research efforts

Apr. 12, 2018—Henry Paul and Dave Robbins, members of country music group BlackHawk, as well as southern rock band The Outlaws, recently donated $40,000 to Vanderbilt-Ingram Cancer Center (VICC) in support of melanoma research. Since 2006, the band members have generated more than $100,000 for VICC.